Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Trial Profile

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Antineoplastics
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AZURE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2017 This trial was completed in Spain, as per European Clinical Trials Database record.
    • 24 Jun 2013 Results from the main study assessing the incidence of jaw osteonecrosis and a substudy assessing oral health-related quality of life published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top